JP2017535612A - リルゾールの舌下投与 - Google Patents

リルゾールの舌下投与 Download PDF

Info

Publication number
JP2017535612A
JP2017535612A JP2017545857A JP2017545857A JP2017535612A JP 2017535612 A JP2017535612 A JP 2017535612A JP 2017545857 A JP2017545857 A JP 2017545857A JP 2017545857 A JP2017545857 A JP 2017545857A JP 2017535612 A JP2017535612 A JP 2017535612A
Authority
JP
Japan
Prior art keywords
riluzole
disorder
sublingual
day
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535612A5 (enExample
Inventor
ウラディミール・コリック
ロバート・エム・バーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of JP2017535612A publication Critical patent/JP2017535612A/ja
Publication of JP2017535612A5 publication Critical patent/JP2017535612A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017545857A 2014-11-21 2015-11-17 リルゾールの舌下投与 Pending JP2017535612A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
US62/083,068 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (2)

Publication Number Publication Date
JP2017535612A true JP2017535612A (ja) 2017-11-30
JP2017535612A5 JP2017535612A5 (enExample) 2018-11-01

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545857A Pending JP2017535612A (ja) 2014-11-21 2015-11-17 リルゾールの舌下投与

Country Status (14)

Country Link
US (1) US20180153862A1 (enExample)
EP (1) EP3220890A1 (enExample)
JP (1) JP2017535612A (enExample)
KR (1) KR20170137030A (enExample)
CN (1) CN107735077A (enExample)
AU (1) AU2015350142A1 (enExample)
BR (1) BR112017010440A2 (enExample)
CA (1) CA2967659A1 (enExample)
EA (1) EA201791110A1 (enExample)
IL (1) IL252283A0 (enExample)
MX (1) MX2017006454A (enExample)
PH (1) PH12017500933A1 (enExample)
SG (1) SG11201703897SA (enExample)
WO (1) WO2016081466A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525714A (ja) * 2018-05-27 2021-09-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． 疾患の処置のためのリルゾール口腔内崩壊錠の使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN107249567B (zh) 2014-11-21 2021-08-03 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CA3036201A1 (en) * 2016-09-15 2018-03-22 Skintech Life Science Limited Sublingual or buccal administration of dim for treatment of skin diseases
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
US10235998B1 (en) * 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
KR20200143710A (ko) * 2018-04-09 2020-12-24 더 제너럴 하스피탈 코포레이션 근위축 측삭 경화증 및 관련 장애의 치료를 위한 조합 요법
EP3836922B1 (en) * 2018-08-16 2024-08-07 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522121A (ja) * 1999-06-04 2003-07-22 フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス 多発性硬化症の処置のためのリルゾールの使用
JP2006519219A (ja) * 2003-02-28 2006-08-24 ブリタニア ファーマシューティカルズ リミテッド 鼻腔送達用医薬品組成物
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
JP2011219497A (ja) * 1998-12-15 2011-11-04 Aventis Pharma Sa 音響性外傷を処置するための薬剤
JP2014520856A (ja) * 2011-07-13 2014-08-25 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
IN2014DN07989A (enExample) * 2012-03-01 2015-05-01 Pharnext

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011219497A (ja) * 1998-12-15 2011-11-04 Aventis Pharma Sa 音響性外傷を処置するための薬剤
JP2003522121A (ja) * 1999-06-04 2003-07-22 フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス 多発性硬化症の処置のためのリルゾールの使用
JP2006519219A (ja) * 2003-02-28 2006-08-24 ブリタニア ファーマシューティカルズ リミテッド 鼻腔送達用医薬品組成物
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
JP2014520856A (ja) * 2011-07-13 2014-08-25 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TROP.J.PHARMA.RES.,2014,13(3),P.459-467, JPN6019030042, ISSN: 0004224791 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525714A (ja) * 2018-05-27 2021-09-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． 疾患の処置のためのリルゾール口腔内崩壊錠の使用

Also Published As

Publication number Publication date
BR112017010440A2 (pt) 2017-12-26
CA2967659A1 (en) 2016-05-26
AU2015350142A1 (en) 2017-06-15
IL252283A0 (en) 2017-07-31
SG11201703897SA (en) 2017-06-29
KR20170137030A (ko) 2017-12-12
CN107735077A (zh) 2018-02-23
PH12017500933A1 (en) 2017-11-20
MX2017006454A (es) 2018-03-23
EA201791110A1 (ru) 2017-11-30
US20180153862A1 (en) 2018-06-07
EP3220890A1 (en) 2017-09-27
WO2016081466A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
JP2017535612A (ja) リルゾールの舌下投与
JP6753860B2 (ja) リルゾールの舌下製剤
JP2018509460A (ja) 炎症疾患及び免疫疾患を治療するための方法及び組成物
CN101636159A (zh) 用于预防和治疗阿尔茨海默型痴呆症的药物
ES2287255T3 (es) Uso de flumazenil para producir un medicamento parta el tratamiento de la dependencia a cocaina.
US10071077B2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
HK40077183A (en) Sublingual formulation of riluzole
HK40024978A (en) Sublingual formulation of riluzole
HK40024978B (en) Sublingual formulation of riluzole
HK1243318A1 (en) Sublingual formulation of riluzole
HK1243318B (en) Sublingual formulation of riluzole

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303